// App-Quantinova.ai

Su2094 : Safety and Dosing Study of Glucagon-Like Peptide 2 (GLP-2) in Children With Intestinal Failure

Researchers

Presenter

  • Viona Lam

Principal Investigators

  • Vikram Karnik

  • Laurie Wallace

  • Jens J. Holst

  • Mary Brindle

  • Bolette Hartmann

  • Dana L. Boctor

  • Linda Casey

  • Bryan Dicken

  • Sharla Stoffman

  • Elaine de Heuvel

  • Gail Wrightwilson

Medical Centers

  • Surgery Pediatric, Stollery Children's Hospital/University of Alberta, Edmonton, AB, Canada

  • Department of Pediatrics, Alberta Childrens Hospital, University of Calgary, Calgary, AB, Canada

  • Department of Pediatrics, Alberta Childrens Hospital, University of Calgary, Calgary, AB, Canada

  • Pediatrics/Rheumatology, British Columbia Children's Hospital, Vancouver, BC, Canada

  • Medical Physiology, the Panum Institute, University of Copenhagen, Copenhagen, Denmark

Locations

  • Canada

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Short bowel syndrome

Biomarkers

  • Glucagon-like peptide-2

Drug/Treatment

  • citrulline

  • Hydroxyzine

  • Intranasal glucagon

Outcome

  • N/A

Study Design

  • open label

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved